Literature DB >> 26962021

Nuclear receptors and nonalcoholic fatty liver disease.

Matthew C Cave1, Heather B Clair2, Josiah E Hardesty2, K Cameron Falkner3, Wenke Feng4, Barbara J Clark2, Jennifer Sidey2, Hongxue Shi5, Bashar A Aqel6, Craig J McClain7, Russell A Prough2.   

Abstract

Nuclear receptors are transcription factors which sense changing environmental or hormonal signals and effect transcriptional changes to regulate core life functions including growth, development, and reproduction. To support this function, following ligand-activation by xenobiotics, members of subfamily 1 nuclear receptors (NR1s) may heterodimerize with the retinoid X receptor (RXR) to regulate transcription of genes involved in energy and xenobiotic metabolism and inflammation. Several of these receptors including the peroxisome proliferator-activated receptors (PPARs), the pregnane and xenobiotic receptor (PXR), the constitutive androstane receptor (CAR), the liver X receptor (LXR) and the farnesoid X receptor (FXR) are key regulators of the gut:liver:adipose axis and serve to coordinate metabolic responses across organ systems between the fed and fasting states. Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease and may progress to cirrhosis and even hepatocellular carcinoma. NAFLD is associated with inappropriate nuclear receptor function and perturbations along the gut:liver:adipose axis including obesity, increased intestinal permeability with systemic inflammation, abnormal hepatic lipid metabolism, and insulin resistance. Environmental chemicals may compound the problem by directly interacting with nuclear receptors leading to metabolic confusion and the inability to differentiate fed from fasting conditions. This review focuses on the impact of nuclear receptors in the pathogenesis and treatment of NAFLD. Clinical trials including PIVENS and FLINT demonstrate that nuclear receptor targeted therapies may lead to the paradoxical dissociation of steatosis, inflammation, fibrosis, insulin resistance, dyslipidemia and obesity. Novel strategies currently under development (including tissue-specific ligands and dual receptor agonists) may be required to separate the beneficial effects of nuclear receptor activation from unwanted metabolic side effects. The impact of nuclear receptor crosstalk in NAFLD is likely to be profound, but requires further elucidation. This article is part of a Special Issue entitled: Xenobiotic nuclear receptors: New Tricks for An Old Dog, edited by Dr. Wen Xie.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  CAR; FXR; LXR; NAFLD; NASH; PCBs; PPAR; PXR; TAFLD; TASH

Mesh:

Substances:

Year:  2016        PMID: 26962021      PMCID: PMC5149456          DOI: 10.1016/j.bbagrm.2016.03.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  249 in total

1.  CAR Suppresses Hepatic Gluconeogenesis by Facilitating the Ubiquitination and Degradation of PGC1α.

Authors:  Jie Gao; Jiong Yan; Meishu Xu; Songrong Ren; Wen Xie
Journal:  Mol Endocrinol       Date:  2015-09-25

2.  Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression.

Authors:  Songtao Yu; Kimihiko Matsusue; Papreddy Kashireddy; Wen-Qing Cao; Vaishalee Yeldandi; Anjana V Yeldandi; M Sambasiva Rao; Frank J Gonzalez; Janardan K Reddy
Journal:  J Biol Chem       Date:  2002-10-24       Impact factor: 5.157

Review 3.  PPARs at the crossroads of lipid signaling and inflammation.

Authors:  Walter Wahli; Liliane Michalik
Journal:  Trends Endocrinol Metab       Date:  2012-06-14       Impact factor: 12.015

4.  Effects of farnesoid X receptor on the expression of the fatty acid synthetase and hepatic lipase.

Authors:  Li-Li Shen; Hong Liu; Jiahe Peng; Lin Gan; Li Lu; Qian Zhang; Liangpeng Li; Fengtian He; Yu Jiang
Journal:  Mol Biol Rep       Date:  2010-04-07       Impact factor: 2.316

5.  Active ERK1/2 protein interacts with the phosphorylated nuclear constitutive active/androstane receptor (CAR; NR1I3), repressing dephosphorylation and sequestering CAR in the cytoplasm.

Authors:  Makoto Osabe; Masahiko Negishi
Journal:  J Biol Chem       Date:  2011-08-26       Impact factor: 5.157

6.  The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease.

Authors:  Silvia Sookoian; Gustavo O Castaño; Adriana L Burgueño; Tomas Fernández Gianotti; María Soledad Rosselli; Carlos Jose Pirola
Journal:  Pharmacogenet Genomics       Date:  2010-01       Impact factor: 2.089

Review 7.  Pleiotropic roles of bile acids in metabolism.

Authors:  Thomas Q de Aguiar Vallim; Elizabeth J Tarling; Peter A Edwards
Journal:  Cell Metab       Date:  2013-04-18       Impact factor: 27.287

8.  Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR.

Authors:  Wolfgang Wistuba; Carsten Gnewuch; Gerhard Liebisch; Gerd Schmitz; Thomas Langmann
Journal:  World J Gastroenterol       Date:  2007-08-21       Impact factor: 5.742

9.  Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.

Authors:  Bertrand Cariou; Rémy Hanf; Stéphanie Lambert-Porcheron; Yassine Zaïr; Valérie Sauvinet; Benoit Noël; Laurent Flet; Hubert Vidal; Bart Staels; Martine Laville
Journal:  Diabetes Care       Date:  2013-05-28       Impact factor: 19.112

Review 10.  Coordinated Actions of FXR and LXR in Metabolism: From Pathogenesis to Pharmacological Targets for Type 2 Diabetes.

Authors:  Lin Ding; Shuguang Pang; Yongmei Sun; Yuling Tian; Li Yu; Ningning Dang
Journal:  Int J Endocrinol       Date:  2014-04-28       Impact factor: 3.257

View more
  81 in total

Review 1.  Mechanisms of Environmental Contributions to Fatty Liver Disease.

Authors:  Banrida Wahlang; Jian Jin; Juliane I Beier; Josiah E Hardesty; Erica F Daly; Regina D Schnegelberger; K Cameron Falkner; Russell A Prough; Irina A Kirpich; Matthew C Cave
Journal:  Curr Environ Health Rep       Date:  2019-09

Review 2.  Endocrine-disrupting chemicals and fatty liver disease.

Authors:  Charles E Foulds; Lindsey S Treviño; Brian York; Cheryl L Walker
Journal:  Nat Rev Endocrinol       Date:  2017-05-19       Impact factor: 43.330

3.  Widespread Dysregulation of Long Noncoding Genes Associated With Fatty Acid Metabolism, Cell Division, and Immune Response Gene Networks in Xenobiotic-exposed Rat Liver.

Authors:  Kritika Karri; David J Waxman
Journal:  Toxicol Sci       Date:  2020-04-01       Impact factor: 4.849

4.  Tubulin alpha 8 is expressed in hepatic stellate cells and is induced in transformed hepatocytes.

Authors:  Lisa Rein-Fischboeck; Rebekka Pohl; Elisabeth M Haberl; Sebastian Zimny; Maximilian Neumann; Kristina Eisinger; Thomas S Weiss; Sabrina Krautbauer; Christa Buechler
Journal:  Mol Cell Biochem       Date:  2017-01-07       Impact factor: 3.396

Review 5.  Role of xenobiotics in the induction and progression of fatty liver disease.

Authors:  James E Klaunig; Xilin Li; Zemin Wang
Journal:  Toxicol Res (Camb)       Date:  2018-05-18       Impact factor: 3.524

6.  Organic solute transporter OSTα/β is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury.

Authors:  Melina M Malinen; Izna Ali; Jacqueline Bezençon; James J Beaudoin; Kim L R Brouwer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-02-08       Impact factor: 4.052

7.  Identifying sex differences arising from polychlorinated biphenyl exposures in toxicant-associated liver disease.

Authors:  Banrida Wahlang; Jian Jin; Josiah E Hardesty; Kimberly Z Head; Hongxue Shi; K Cameron Falkner; Russell A Prough; Carolyn M Klinge; Matthew C Cave
Journal:  Food Chem Toxicol       Date:  2019-04-23       Impact factor: 6.023

8.  Unexpected metabolic disorders induced by endocrine disruptors in Xenopus tropicalis provide new lead for understanding amphibian decline.

Authors:  Christophe Regnault; Marie Usal; Sylvie Veyrenc; Karine Couturier; Cécile Batandier; Anne-Laure Bulteau; David Lejon; Alexandre Sapin; Bruno Combourieu; Maud Chetiveaux; Cédric Le May; Thomas Lafond; Muriel Raveton; Stéphane Reynaud
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-23       Impact factor: 11.205

9.  Liver Disease in a Residential Cohort With Elevated Polychlorinated Biphenyl Exposures.

Authors:  Heather B Clair; Christina M Pinkston; Shesh N Rai; Marian Pavuk; Nina D Dutton; Guy N Brock; Russell A Prough; Keith Cameron Falkner; Craig J McClain; Matthew C Cave
Journal:  Toxicol Sci       Date:  2018-07-01       Impact factor: 4.849

10.  Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease.

Authors:  Hong Zhang; Zhe Shen; Yiming Lin; Jie Zhang; Yuwei Zhang; Peihao Liu; Hang Zeng; Mengli Yu; Xueyang Chen; Longgui Ning; Xinli Mao; Li Cen; Chaohui Yu; Chengfu Xu
Journal:  J Biol Chem       Date:  2020-02-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.